Treatment with an apoC-III antisense oligonucleotide also reduces circulating apoC-III levels, delays disease onset in a rat model of T1D and improves glucose tolerance in insulin-resistant ob/ob mice [66,96]. Here, APOC3 is linked to type 1 diabetes mellitus.